Expanded access protocol with abiraterone acetate for metastatic castration-resistant prostate cancer post-chemotherapy – results in Czech Republic

European Urology Supplements ◽

10.1016/s1569-9056(16)30243-3 ◽

2016 ◽

Vol 15 (11) ◽

pp. e1394

Author(s):

T. Hradec ◽

O. Capoun ◽

R. Sobotka ◽

M. Pesl ◽

V. Soukup ◽

...

Keyword(s):

Prostate Cancer ◽

Czech Republic ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Access Protocol ◽

Expanded Access ◽

Castration Resistant

Download Full-text

Final analysis of a large, open-label global early access protocol (EAP) with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after chemotherapy.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.5061 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 5061-5061

Author(s):

Cora N. Sternberg ◽

Gedske Daugaard ◽

Lajos Geczi ◽

Sebastien J. Hotte ◽

Paul N. Mainwaring ◽

...

Keyword(s):

Prostate Cancer ◽

Final Analysis ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Access Protocol ◽

Early Access ◽

Castration Resistant

Download Full-text

Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70417-6 ◽

2014 ◽

Vol 15 (11) ◽

pp. 1263-1268 ◽

Author(s):

Cora N Sternberg ◽

Daniel Castellano ◽

Gedske Daugaard ◽

Lajos Géczi ◽

Sebastien J Hotte ◽

...

Keyword(s):

Prostate Cancer ◽

Final Analysis ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Access Protocol ◽

Early Access ◽

Castration Resistant

Download Full-text

557 Early access protocol with abiraterone acetate for European patients with metastatic castration-resistant prostate cancer progressing after chemotherapy

European Urology Supplements ◽

10.1016/s1569-9056(15)60550-4 ◽

2015 ◽

Vol 14 (2) ◽

pp. e557-e557a

Author(s):

D. Castellano ◽

S. Bracarda ◽

M. Tucci ◽

O. Capoun ◽

V. Matveev ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Access Protocol ◽

Early Access ◽

Castration Resistant

Download Full-text

Analysis of European Patients Enrolled in a Global Early Access Protocol with Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer Progressing After Chemotherapy

Annals of Oncology ◽

10.1093/annonc/mdu336.29 ◽

2014 ◽

Vol 25 ◽

pp. iv269 ◽

Author(s):

D. Castellano ◽

S. Bracarda ◽

M. Tucci ◽

O. Capoun ◽

V. Matveev ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Access Protocol ◽

Early Access ◽

Castration Resistant

Download Full-text

81P Safety and effectiveness of apalutamide for the treatment of non-metastatic castration-resistant prostate cancer (nm-CRPC): Preliminary results from an open-label expanded access protocol (EAP)

Annals of Oncology ◽

10.1016/j.annonc.2021.08.2077 ◽

2021 ◽

Vol 32 ◽

pp. S1370

Author(s):

S. Campos-Gomez ◽

J.C. Ochoa ◽

F. Cruz ◽

A. Mota ◽

M.A.J. Rios ◽

...

Keyword(s):

Prostate Cancer ◽

Castration Resistant Prostate Cancer ◽

Access Protocol ◽

Preliminary Results ◽

Expanded Access ◽

Castration Resistant

Download Full-text

18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Abiraterone Acetate

Case Medical Research ◽

10.31525/ct1-nct04158245 ◽

2019 ◽

Author(s):

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

Faculty Opinions recommendation of Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1118816.793494158 ◽

2014 ◽

Author(s):

Thomas Flaig

Keyword(s):

Prostate Cancer ◽

Clinical Trial ◽

Phase I ◽

Abiraterone Acetate ◽

Selective Inhibitor ◽

Phase I Clinical Trial ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

Faculty Opinions recommendation of Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717999366.793474668 ◽

2013 ◽

Author(s):

Michael Glode

Keyword(s):

Prostate Cancer ◽

Antitumour Activity ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

A Rapid, Direct and Validated HPLC- Fluorescence Method for the Quantification of Abiraterone and Abiraterone Acetate in Urine and Serum Samples from Patients with Castration- Resistant Prostate Cancer

Current Pharmaceutical Analysis ◽

10.2174/1573412913666170213152002 ◽

2018 ◽

Vol 14 (3) ◽

pp. 233-238 ◽

Author(s):

Juana Rodriguez ◽

Gregorio Castaneda ◽

Isabel Lizcano ◽

Jose C. Villa

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Fluorescence Method ◽

Castration Resistant Prostate Cancer ◽

Serum Samples ◽

Castration Resistant ◽

Urine And Serum

Download Full-text

Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer

Current Medical Research and Opinion ◽

10.1080/03007995.2021.1888704 ◽

2021 ◽

Vol 37 (4) ◽

pp. 635-642

Author(s):

Stephen J. Freedland ◽

Sophia Li ◽

Dominic Pilon ◽

Rachel H. Bhak ◽

Sahil Narkhede ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Psa Progression

Download Full-text